Publications by authors named "Aya Zakaria"

Fasting regimens have shown profound impact on pro-longevity and tissue regeneration in diverse species. Physiological events can induce a regenerative response in adult stem cells. However, little is known about signaling and activation of adult stem cells which are modulated by fasting.

View Article and Find Full Text PDF
Article Synopsis
  • - Sickle Cell Disease (SCD) is a serious inherited blood disorder primarily affecting individuals in West Africa, India, and the Mediterranean, leading to severe complications and higher mortality.
  • - Hydroxyurea is the main treatment for SCD, supplemented by additional drugs like L-glutamine, Voxelotor, and Crizanlizumab, but none cure the disease; hematopoietic stem cell transplantation is the only curative option.
  • - The emergence of gene-editing techniques shows potential in treating SCD, though they are expensive, prompting a need for cost-effective evaluations to inform future treatment decisions.
View Article and Find Full Text PDF

Objectives: Given the success of combination antiretroviral therapy (cART) in treating HIV viremia, drug toxicity remains an area of interest in HIV research. Despite newer integrase strand transfer inhibitors (InSTIs), such as dolutegravir (DTG) and raltegravir (RAL), having excellent clinical tolerance, there is emerging evidence of off-target effects and toxicities. Although limited in number, recent reports have highlighted the vulnerability of mitochondria to these toxicities.

View Article and Find Full Text PDF

The aim of the present study was to examine the neuroprotective potential of pioglitazone via activation of Nrf2/ARE-dependent HO-1 signaling pathway in chronic neuroinflammation and progressive neurodegeneration mouse model induced by lipopolysaccharide (LPS). After assessing spatial memory, anxiety and motor-coordination, TH+ neurons in substantia nigra (SN) were counted. The oxidative stress marker carbonyl protein levels and HO-1 enzyme activity were also evaluated.

View Article and Find Full Text PDF

Methylene blue (MB) phase II clinical trials reported improvements in cognitive functions of Alzheimer's disease (AD) patients. Regarding MB mechanism of action, its antioxidant and mitochondrial protective effects have been previously described. In relation to AD, it has been recently reported that MB reduced amyloid beta (Aβ) levels in AD models.

View Article and Find Full Text PDF